VRTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.20%

Insider Buying (Last 12 Months): $1,948,400.00

Insider Selling (Last 12 Months): $34,435,486.66

Vertex Pharmaceuticals Insider Trading History Chart

Vertex Pharmaceuticals Share Price & Price History

^$458.39

▲ +1.032 (0.23%)

As of 12/5/2025 11:33 AM ET

Days: 30 | 90 | 365

Vertex Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/14/2025	Jeffrey M. Leiden	Chairman	Sell	53,604	$440.72	$23,624,354.88	24,026
11/13/2025	Jeffrey M. Leiden	Chairman	Sell	19,688	$440.27	$8,668,035.76	24,026
8/6/2025	Bruce I. Sachs	Director	Buy	5,000	$389.68	$1,948,400.00	45,000
5/15/2025	David Altshuler	EVP	Sell	52	$424.69	$22,083.88	23,281
3/10/2025	David Altshuler	EVP	Sell	3,231	$500.00	$1,615,500.00	26,512
2/27/2025	Ourania Tatsis	EVP	Sell	530	$475.34	$251,930.20	58,539
2/18/2025	Ourania Tatsis	EVP	Sell	244	$455.06	$111,034.64	67,695
2/11/2025	Ourania Tatsis	EVP	Sell	310	$459.83	$142,547.30	64,021
11/15/2024	David Altshuler	EVP	Sell	15	$478.56	$7,178.40	25,813
8/30/2024	Jeffrey M. Leiden	Chairman	Sell	3,784	$499.00	$1,888,216.00	9,994
8/30/2024	Sangeeta N Bhatia	Director	Sell	646	$500.00	$323,000.00	4,435
8/7/2024	Carmen Bozic	CMO	Sell	2,280	$476.75	$1,086,990.00	23,259
8/1/2024	Bruce I. Sachs	Director	Sell	5,295	$508.00	$2,689,860.00	40,000
7/24/2024	Carmen Bozic	CMO	Sell	2,280	$488.46	$1,113,688.80	25,539
7/22/2024	Reshma Kewalramani	CEO	Sell	15,202	$497.00	$7,555,394.00	106,172
7/10/2024	Carmen Bozic	CMO	Sell	2,280	$487.34	$1,111,135.20	27,819
6/26/2024	Carmen Bozic	CMO	Sell	2,280	$471.72	$1,075,521.60	30,099
6/12/2024	Carmen Bozic	CMO	Sell	2,280	$478.00	$1,089,840.00	32,379
6/12/2024	E. Morrey Atkinson, III	EVP	Sell	7,288	$478.00	$3,483,664.00	15,972
5/30/2024	Ourania Tatsis	EVP	Sell	2,350	$439.11	$1,031,908.50	53,523
5/29/2024	Carmen Bozic	CMO	Sell	2,280	$445.56	$1,015,876.80	34,659
5/28/2024	Charles F. Wagner, Jr.	CFO	Sell	3,250	$454.79	$1,478,067.50	50,387
5/24/2024	Reshma Kewalramani	CEO	Sell	1,565	$457.00	$715,205.00	121,374
5/22/2024	Bruce I. Sachs	Director	Sell	7,073	$448.00	$3,168,704.00	40,000
2/26/2024	Ourania Tatsis	EVP	Sell	354	$425.70	$150,697.80	55,804
2/20/2024	Ourania Tatsis	EVP	Sell	480	$420.79	$201,979.20	59,827
2/12/2024	Amit Sachdev	EVP	Sell	3,222	$420.24	$1,354,013.28	74,364
2/12/2024	Jeffrey M. Leiden	Chairman	Sell	2,656	$419.51	$1,114,218.56	27,644
2/12/2024	Kristen Ambrose	CAO	Sell	1,374	$420.24	$577,409.76	9,676
2/12/2024	Stuart A. Arbuckle	COO	Sell	4,295	$420.24	$1,804,930.80	75,718
1/8/2024	Jeffrey M. Leiden	Chairman	Sell	6,648	$419.07	$2,785,977.36	2,423
11/6/2023	Bruce I. Sachs	Director	Sell	11,250	$385.00	$4,331,250.00	40,000
10/31/2023	Carmen Bozic	CMO	Sell	5,651	$355.92	$2,011,303.92	34,952
10/17/2023	Carmen Bozic	CMO	Sell	5,651	$373.25	$2,109,235.75	40,603
10/17/2023	Sangeeta N Bhatia	Director	Sell	243	$375.00	$91,125.00	3,901
10/16/2023	Jeffrey M. Leiden	Chairman	Sell	12,962	$374.00	$4,847,788.00	22,425
10/6/2023	Sangeeta N Bhatia	Director	Sell	242	$360.00	$87,120.00	4,144
10/3/2023	Carmen Bozic	CMO	Sell	5,651	$345.28	$1,951,177.28	46,254
10/2/2023	Jonathan Biller	EVP	Sell	610	$346.76	$211,523.60	10,569
9/19/2023	Carmen Bozic	CMO	Sell	5,651	$351.00	$1,983,501.00	51,905
8/23/2023	Ourania Tatsis	EVP	Sell	2,500	$355.00	$887,500.00	48,637
8/9/2023	David Altshuler	EVP	Sell	63	$345.51	$21,767.13	32,038
8/9/2023	Sangeeta N Bhatia	Director	Sell	242	$345.51	$83,613.42	4,386
7/17/2023	Bruce I. Sachs	Director	Sell	11,250	$356.75	$4,013,437.50	40,000
7/17/2023	Reshma Kewalramani	CEO	Sell	7,828	$355.00	$2,778,940.00	118,906
6/15/2023	Stuart A. Arbuckle	COO	Sell	8,603	$349.00	$3,002,447.00	56,556
5/30/2023	Kristen Ambrose	CAO	Sell	289	$329.82	$95,317.98	6,838
5/30/2023	Stuart A. Arbuckle	COO	Sell	82	$329.82	$27,045.24	56,556
5/8/2023	Bastiano Sanna	EVP	Sell	2,850	$350.00	$997,500.00	32,038
5/8/2023	Jeffrey M. Leiden	Chairman	Sell	1,125	$349.00	$392,625.00	35,387
5/5/2023	Bastiano Sanna	EVP	Sell	422	$350.03	$147,712.66	34,888
5/5/2023	Jeffrey M. Leiden	Chairman	Sell	879	$349.56	$307,263.24	36,512
5/2/2023	Bastiano Sanna	EVP	Sell	1,622	$350.66	$568,770.52	38,091
5/2/2023	Jeffrey M. Leiden	Chairman	Sell	6,450	$349.89	$2,256,790.50	41,899
5/2/2023	Sangeeta N Bhatia	Director	Sell	580	$348.28	$202,002.40	4,628
4/27/2023	Reshma Kewalramani	CEO	Sell	3,317	$339.08	$1,124,728.36	126,652
4/12/2023	Bastiano Sanna	EVP	Sell	7,567	$326.70	$2,472,138.90	39,713
4/12/2023	Bruce I. Sachs	Director	Sell	21,300	$326.73	$6,959,349.00	41,210
4/4/2023	Bastiano Sanna	EVP	Sell	522	$315.81	$164,852.82	47,280
3/24/2023	Charles F. Wagner, Jr.	CFO	Sell	1,768	$305.38	$539,911.84	49,611
3/17/2023	Charles F. Wagner, Jr.	CFO	Sell	2,000	$296.39	$592,780.00	51,379
3/16/2023	Bastiano Sanna	EVP	Sell	2,746	$300.59	$825,420.14	49,268
3/13/2023	Charles F. Wagner, Jr.	CFO	Sell	2,666	$293.83	$783,350.78	53,379
3/10/2023	Charles F. Wagner, Jr.	CFO	Sell	2,088	$289.61	$604,705.68	56,045
2/27/2023	Kristen Ambrose	CAO	Sell	1,207	$287.55	$347,072.85	7,303
2/27/2023	Ourania Tatsis	EVP	Sell	354	$287.48	$101,767.92	56,805
2/27/2023	Stuart A. Arbuckle	COO	Sell	5,034	$287.47	$1,447,123.98	56,556
2/22/2023	Stuart A. Arbuckle	COO	Sell	2,401	$294.33	$706,686.33	66,304
2/13/2023	Ourania Tatsis	EVP	Sell	275	$298.99	$82,222.25	65,765
2/13/2023	Stuart A. Arbuckle	COO	Sell	4,887	$298.92	$1,460,822.04	82,003
2/6/2023	David Altshuler	EVP	Sell	1,304	$306.00	$399,024.00	68,645
1/30/2023	Lloyd Carney	Director	Sell	2,700	$320.52	$865,404.00	4,150
1/27/2023	Yuchun Lee	Director	Sell	1,429	$322.03	$460,180.87	1,875
1/25/2023	Reshma Kewalramani	CEO	Sell	10,000	$315.05	$3,150,500.00	89,598
1/25/2023	Yuchun Lee	Director	Sell	4,000	$313.96	$1,255,840.00	1,875
1/23/2023	Yuchun Lee	Director	Sell	2,129	$312.02	$664,290.58	1,875
1/18/2023	Yuchun Lee	Director	Sell	442	$312.17	$137,979.14	1,875

SEC Filings (Institutional Ownership Changes) for Vertex Pharmaceuticals (NASDAQ:VRTX)

90.96% of Vertex Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Vertex Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
12/2/2025	Allworth Financial LP	2,730	$1.07M	0.0%	-21.1%	0.001%
12/2/2025	IFP Advisors Inc	2,188	$0.94M	0.0%	+37.6%	0.001%
12/2/2025	Swiss Life Asset Management Ltd	63,945	$25.04M	0.1%	+10.4%	0.025%
12/1/2025	Groupama Asset Managment	43,381	$16.99M	0.1%	-29.2%	0.017%
12/1/2025	Cambria Investment Management L.P.	4,181	$1.64M	0.1%	+6.9%	0.002%
11/24/2025	CIBC Private Wealth Group LLC	6,798	$2.66M	0.0%	-3.3%	0.003%
11/21/2025	CIBC Bancorp USA Inc.	44,774	$17.54M	0.1%	N/A	0.018%
11/21/2025	Oarsman Capital Inc.	4,716	$1.85M	0.3%	+7.5%	0.002%
11/20/2025	Centaurus Financial Inc.	3,027	$1.19M	0.1%	+27.6%	0.001%
11/20/2025	Wilmington Savings Fund Society FSB	629	$0.25M	0.0%	-82.8%	0.000%
11/20/2025	First Affirmative Financial Network	1,015	$0.40M	0.2%	-10.4%	0.000%
11/20/2025	Tweedy Browne Co LLC	39,065	$15.30M	1.3%	+4.9%	0.015%
11/19/2025	First Commonwealth Financial Corp PA	1,135	$0.44M	0.1%	-5.6%	0.000%
11/19/2025	Captrust Financial Advisors	12,074	$4.73M	0.0%	-9.3%	0.005%
11/19/2025	Coldstream Capital Management Inc.	6,406	$2.51M	0.0%	+9.1%	0.003%
11/19/2025	Danske Bank A S	164,480	$64.42M	0.2%	N/A	0.065%
11/19/2025	Second Line Capital LLC	1,115	$0.44M	0.1%	N/A	0.000%
11/19/2025	Provident Investment Management Inc.	153,406	$60.08M	5.3%	-3.3%	0.060%
11/18/2025	Advisory Services Network LLC	4,847	$1.90M	0.0%	-20.8%	0.002%
11/17/2025	Peloton Wealth Strategists	7,875	$3.08M	1.2%	-3.4%	0.003%
11/17/2025	Jacobs Levy Equity Management Inc.	24,949	$9.77M	0.0%	-51.0%	0.010%
11/17/2025	Morningstar Investment Management LLC	12,305	$4.82M	0.2%	+900.4%	0.005%
11/17/2025	Kestra Private Wealth Services LLC	10,254	$4.02M	0.1%	+67.4%	0.004%
11/17/2025	NewEdge Advisors LLC	11,718	$4.59M	0.0%	-1.8%	0.005%
11/17/2025	Reynders McVeigh Capital Management LLC	55,350	$21.68M	1.0%	+1.9%	0.022%
11/17/2025	Armistice Capital LLC	40,239	$15.76M	0.2%	N/A	0.016%
11/17/2025	CANADA LIFE ASSURANCE Co	274,136	$108.35M	0.2%	+1.3%	0.108%
11/17/2025	Woodline Partners LP	153,272	$60.03M	0.3%	+67.2%	0.060%
11/17/2025	CYBER HORNET ETFs LLC	695	$0.27M	0.2%	+4.0%	0.000%
11/17/2025	Blue Chip Partners LLC	1,375	$0.54M	0.0%	+24.3%	0.001%
11/17/2025	Triumph Capital Management	110	$43K	0.0%	N/A	0.000%
11/17/2025	Dark Forest Capital Management LP	2,010	$0.79M	0.0%	N/A	0.001%
11/17/2025	XTX Topco Ltd	9,690	$3.80M	0.2%	+114.1%	0.004%
11/17/2025	Alyeska Investment Group L.P.	267,169	$104.63M	0.3%	+311.0%	0.105%
11/17/2025	United Capital Financial Advisors LLC	11,512	$4.51M	0.0%	-12.3%	0.005%
11/17/2025	Utah Retirement Systems	42,499	$16.64M	0.2%	-0.1%	0.017%
11/17/2025	Voleon Capital Management LP	10,830	$4.24M	0.1%	+302.2%	0.004%
11/17/2025	Voloridge Investment Management LLC	105,502	$41.32M	0.1%	N/A	0.042%
11/17/2025	Wimmer Associates 1 LLC	5,455	$2.14M	1.0%	-2.4%	0.002%
11/17/2025	Verition Fund Management LLC	11,544	$4.52M	0.0%	-50.3%	0.005%
11/17/2025	Tidal Investments LLC	14,632	$5.73M	0.0%	+2.6%	0.006%
11/17/2025	State Street Corp	11,606,000	$4.55B	0.2%	-1.4%	4.574%
11/17/2025	Scientech Research LLC	2,578	$1.01M	0.4%	N/A	0.001%
11/17/2025	Sculati Wealth Management LLC	3,328	$1.30M	0.5%	+4.7%	0.001%
11/17/2025	Shelton Capital Management	36,679	$14.37M	0.3%	-30.8%	0.014%
11/17/2025	Polymer Capital Management US LLC	2,082	$0.82M	0.1%	N/A	0.001%
11/17/2025	Prosperity Consulting Group LLC	3,048	$1.19M	0.1%	+3.3%	0.001%
11/17/2025	Prosperity Wealth Management Inc.	1,757	$0.69M	0.2%	N/A	0.001%
11/17/2025	Quadcap Wealth Management LLC	1,337	$0.52M	0.1%	N/A	0.001%
11/17/2025	Public Employees Retirement System of Ohio	102,732	$40.23M	0.1%	-3.1%	0.040%
11/17/2025	Northwestern Mutual Wealth Management Co.	8,307	$3.25M	0.0%	-28.0%	0.003%
11/17/2025	Northern Trust Corp	2,627,887	$1.03B	0.1%	-1.2%	1.036%
11/17/2025	Norinchukin Bank The	22,026	$8.63M	0.1%	+0.4%	0.009%
11/17/2025	Mariner LLC	110,251	$43.19M	0.1%	-7.4%	0.043%
11/17/2025	Moors & Cabot Inc.	3,579	$1.40M	0.1%	-13.4%	0.001%
11/17/2025	National Bank of Canada FI	247,941	$97.10M	0.1%	+3.1%	0.098%
11/17/2025	Mercer Global Advisors Inc. ADV	18,784	$7.36M	0.0%	+1.4%	0.007%
11/17/2025	Mirabella Financial Services LLP	5,377	$2.10M	0.1%	+133.9%	0.002%
11/17/2025	Moneta Group Investment Advisors LLC	1,177	$0.46M	0.0%	-5.5%	0.000%
11/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	165,945	$65M	0.1%	-24.4%	0.065%
11/17/2025	Laird Norton Wetherby Wealth Management LLC	5,470	$2.14M	0.1%	-3.6%	0.002%
11/17/2025	Larson Financial Group LLC	863	$0.34M	0.0%	+6.4%	0.000%
11/17/2025	Lighthouse Investment Partners LLC	2,500	$0.98M	0.0%	N/A	0.001%
11/17/2025	Integrated Wealth Concepts LLC	4,574	$1.79M	0.0%	+5.6%	0.002%
11/17/2025	JPL Wealth Management LLC	128	$50K	0.0%	N/A	0.000%
11/17/2025	Hilltop Holdings Inc.	4,934	$1.93M	0.1%	+18.1%	0.002%
11/17/2025	Humankind Investments LLC	2,864	$1.12M	0.3%	+15.1%	0.001%
11/17/2025	Gotham Asset Management LLC	21,888	$8.57M	0.0%	+2.5%	0.009%
11/17/2025	Fagan Associates Inc.	26,306	$10.30M	1.4%	+0.4%	0.010%
11/17/2025	Fayez Sarofim & Co	10,058	$3.94M	0.0%	-2.9%	0.004%
11/17/2025	First Commonwealth Financial Corp PA	1,135	$0.44M	0.2%	-5.6%	0.000%
11/17/2025	Fred Alger Management LLC	3,036	$1.19M	0.0%	-50.8%	0.001%
11/17/2025	Focus Partners Wealth	139,215	$54.52M	0.1%	-2.7%	0.055%
11/17/2025	Fort Point Capital Partners LLC	587	$0.23M	0.0%	-17.1%	0.000%
11/17/2025	Destination Wealth Management	1,642	$0.64M	0.0%	+5.7%	0.001%
11/17/2025	Elevation Point Wealth Partners LLC	1,685	$0.66M	0.0%	+406.0%	0.001%
11/17/2025	EagleClaw Capital Managment LLC	7,385	$2.89M	0.4%	-2.6%	0.003%
11/17/2025	Calydon Capital	2,345	$0.92M	0.1%	-39.4%	0.001%
11/17/2025	Cannell & Spears LLC	1,960	$0.77M	0.0%	+4.7%	0.001%
11/17/2025	Cavalier Investments LLC	7,807	$2.79M	0.2%	+5.0%	0.003%
11/17/2025	Ceeto Capital Group LLC	2,056	$0.81M	0.2%	N/A	0.001%
11/17/2025	Chevy Chase Trust Holdings LLC	418,509	$163.91M	0.5%	-5.1%	0.165%
11/17/2025	Clark Capital Management Group Inc.	572	$0.22M	0.0%	+18.9%	0.000%
11/17/2025	Community Bank N.A.	2,862	$1.12M	0.1%	+45.7%	0.001%
11/17/2025	Ausdal Financial Partners Inc.	1,513	$0.59M	0.0%	+96.5%	0.001%
11/17/2025	Azimuth Capital Investment Management LLC	20,348	$7.97M	0.3%	-3.3%	0.008%
11/17/2025	Bamco Inc. NY	5,200	$2.04M	0.0%	-42.2%	0.002%
11/17/2025	Banco Bilbao Vizcaya Argentaria S.A.	98,153	$38.43M	0.3%	+4.8%	0.039%
11/17/2025	California Public Employees Retirement System	612,507	$239.88M	0.1%	-15.5%	0.241%
11/17/2025	Bank of Nova Scotia	86,252	$33.78M	0.1%	+73.9%	0.034%
11/17/2025	BNP Paribas	5,341	$2.09M	0.1%	-4.2%	0.002%
11/17/2025	Boothbay Fund Management LLC	611	$0.24M	0.0%	+15.3%	0.000%
11/17/2025	Anchor Investment Management LLC	2,387	$0.94M	0.1%	+47.6%	0.001%
11/17/2025	Aquatic Capital Management LLC	29,596	$11.59M	0.2%	N/A	0.012%
11/17/2025	Aristotle Atlantic Partners LLC	39,804	$15.59M	0.5%	-12.3%	0.016%
11/17/2025	1248 Management LLC	1,281	$0.50M	0.3%	-28.6%	0.001%
11/17/2025	1858 Wealth Management LLC	3,542	$1.39M	1.0%	+43.8%	0.001%
11/17/2025	Alliancebernstein L.P.	4,522,586	$1.77B	0.6%	+3.3%	1.783%
11/17/2025	Ameriprise Financial Inc.	2,276,927	$891.74M	0.2%	+4.4%	0.897%
11/14/2025	Ashford Capital Management Inc.	8,245	$3.23M	0.4%	+7.0%	0.003%

Data available starting January 2016

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $458.39

$457.20

$462.00

50 Day Range

MA: $420.74

$385.73

$463.13

52 Week Range

Now: $458.39

$362.50

$519.68

Volume

131,950 shs

Average Volume

1,596,629 shs

Market Capitalization

$116.30 billion

P/E Ratio

32.35

Dividend Yield

N/A

Beta

0.32

Who are the company insiders with the largest holdings of Vertex Pharmaceuticals?: Vertex Pharmaceuticals' top insider shareholders include:
Reshma Kewalramani (CEO)
Stuart A Arbuckle (COO)
Amit Sachdev (EVP)
Ourania Tatsis (EVP)
Charles F Wagner Jr (CFO)
Bruce I Sachs (Director)
Carmen Bozic (CMO)
Jeffrey M Leiden (Chairman)
David Altshuler (EVP)
Edward Morrow Atkinson III (EVP)
Kristen Ambrose (CAO)
Sangeeta N Bhatia (Director)
Learn More about top insider investors at Vertex Pharmaceuticals.
Who are the major institutional investors of Vertex Pharmaceuticals?: Vertex Pharmaceuticals' top institutional investors include:
Capital World Investors — 10.21%
Vanguard Group Inc. — 9.45%
Capital Research Global Investors — 6.52%
State Street Corp — 4.57%
Wellington Management Group LLP — 1.88%
Capital International Investors — 1.85%
Learn More about top institutional investors of Vertex Pharmaceuticals stock.
Which major investors are selling Vertex Pharmaceuticals stock?: Within the previous quarter, VRTX stock was sold by these institutional investors:
Capital World Investors
Jennison Associates LLC
Massachusetts Financial Services Co. MA
Voya Investment Management LLC
TD Asset Management Inc
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC
State Street Corp
Sei Investments Co.
In the last year, company insiders that have sold Vertex Pharmaceuticals company stock include:
Reshma Kewalramani (CEO)
Stuart A Arbuckle (COO)
Amit Sachdev (EVP)
Learn More investors selling Vertex Pharmaceuticals stock.
Which major investors are buying Vertex Pharmaceuticals stock?: During the previous quarter, VRTX stock was acquired by institutional investors including:
Capital International Investors
Assenagon Asset Management S.A.
Capital Research Global Investors
Nordea Investment Management AB
Arrowstreet Capital Limited Partnership
Vanguard Group Inc.
Rakuten Investment Management Inc.
Manning & Napier Advisors LLC